About Athira Pharma, Inc.
https://www.athira.comAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
CEO
Mark J. Litton
Compensation Summary
(Year 2024)
Salary $625,000
Stock Awards $138,353
Option Awards $1,991,260
Incentive Plan Pay $395,313
All Other Compensation $25,085
Total Compensation $3,175,009
Industry Biotechnology
Sector Healthcare
Went public September 18, 2020
Method of going public IPO
Full time employees 26
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-18 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 14
Showing Top 3 of 14
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 3
Price Target
Target High $4
Target Low $4
Target Median $4
Target Consensus $4
Institutional Ownership
BLACKROCK INC.
Shares:676.24K
Value:$4.56M
PATHSTONE FAMILY OFFICE, LLC
Shares:425.49K
Value:$2.87M
PRICE MICHAEL F
Shares:200K
Value:$1.35M
Summary
% Of Shares Owned 43.97%
Total Number Of Holders 17
Showing Top 3 of 17
Market Cap $28.36 M
52w High $8.36
52w Low $2.20
P/E -0.7
Volume 113.99K
Outstanding Shares 3.94M
About Athira Pharma, Inc.
https://www.athira.comAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $6.63M ▼ | $-6.61M ▲ | 0% | $-1.68 ▲ | $-6.5M ▲ |
| Q2-2025 | $0 | $7.09M ▼ | $-6.97M ▲ | 0% | $-1.78 ▲ | $-6.77M ▲ |
| Q1-2025 | $0 | $9.29M ▼ | $-9.14M ▲ | 0% | $-2.3 ▲ | $-8.9M ▲ |
| Q4-2024 | $0 | $15.57M ▼ | $-15M ▲ | 0% | $-3.9 ▲ | $-15.32M ▲ |
| Q3-2024 | $0 | $29.62M | $-28.74M | 0% | $-7.5 | $-25.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $25.23M ▼ | $30.03M ▼ | $3.25M ▼ | $26.79M ▼ |
| Q2-2025 | $29.82M ▼ | $35.55M ▼ | $3.56M ▼ | $31.99M ▼ |
| Q1-2025 | $36.67M ▼ | $43.51M ▼ | $6.18M ▼ | $37.33M ▼ |
| Q4-2024 | $51.27M ▼ | $58.78M ▼ | $13.94M ▼ | $44.84M ▼ |
| Q3-2024 | $68.86M | $86.25M | $28.66M | $57.58M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.61M ▲ | $-4.67M ▲ | $5.65M ▲ | $0 ▼ | $986K ▲ | $-4.67M ▲ |
| Q2-2025 | $-6.97M ▲ | $-7M ▲ | $441K ▲ | $24K ▲ | $-6.53M ▲ | $-7M ▲ |
| Q1-2025 | $-9.14M ▲ | $-14.66M ▲ | $-7.35M ▼ | $0 ▼ | $-22.02M ▲ | $-14.66M ▲ |
| Q4-2024 | $-15M ▲ | $-26.01M ▼ | $-2.81M ▼ | $34K ▲ | $-28.79M ▼ | $-26.01M ▼ |
| Q3-2024 | $-28.74M | $-23.02M | $18.04M | $12K | $-4.97M | $-23.02M |
CEO
Mark J. Litton
Compensation Summary
(Year 2024)
Salary $625,000
Stock Awards $138,353
Option Awards $1,991,260
Incentive Plan Pay $395,313
All Other Compensation $25,085
Total Compensation $3,175,009
Industry Biotechnology
Sector Healthcare
Went public September 18, 2020
Method of going public IPO
Full time employees 26
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-18 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Total 14
Showing Top 3 of 14
Ratings Snapshot
Rating : B
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 3
Price Target
Target High $4
Target Low $4
Target Median $4
Target Consensus $4
Institutional Ownership
BLACKROCK INC.
Shares:676.24K
Value:$4.56M
PATHSTONE FAMILY OFFICE, LLC
Shares:425.49K
Value:$2.87M
PRICE MICHAEL F
Shares:200K
Value:$1.35M
Summary
% Of Shares Owned 43.97%
Total Number Of Holders 17
Showing Top 3 of 17